A multilevel object-oriented modelling methodology for physiologically-based pharmacokinetics (PBPK): Evaluation with a semi-mechanistic pharmacokinetic model

被引:4
|
作者
Reig-Lopez, J. [1 ,2 ]
Merino-Sanjuan, M. [1 ,2 ]
Mangas-Sanjuan, V [1 ,2 ]
Prado-Velasco, M. [3 ,4 ]
机构
[1] Univ Valencia, Sch Pharm, Dept Pharm & Pharmaceut Technol & Parasitol, Av Vicent Andres Estelles S-N, Valencia 46100, Spain
[2] Polytech Univ Valencia Univ Valencia, Interuniv Res Inst Mol Recognit & Technol Dev, Valencia, Spain
[3] Univ Seville, Multiscale Modeling Bioengn Res Grp, Seville, Spain
[4] Univ Seville, Dept Graph Engn, Seville, Spain
关键词
PBPK; Acausal modelling; Semi-mechanistic; Intrinsic clearance; P-glycoprotein; Metabolites; BIOEQUIVALENCE TRIALS SELECTION; COMPUTER-SIMULATIONS; BCS DRUGS; ANALYTE; METABOLISM;
D O I
10.1016/j.cmpb.2020.105322
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Background and objective: The aims of this study are (i) to assess the predictive reliability of the physiologically based software PhysPK versus the well-known population approach software NONMEM for the cited semi-mechanistic PK model, (ii) to determine whether these modelling approaches are interchangeable and (iii) to compare acausal with causal modelling approaches in the framework of semi-mechanistic PK models. Methods: A semi-mechanistic model was proposed, which assumed oral administration of a solid dosage form with a peripheral compartment and two active metabolites. The model incorporates intestinal transit, dissolution limited by solubility, variable efflux transporter expression along the gut and linear and non-linear metabolism in the gut and liver. Four different approximations to the theoretical model were developed in order to validate both the new software and modelling methodology. Results: Plasmatic concentrations correlation plots as well as relative errors in AUC(0-)(48) and C-max predictions revealed the accuracy of PhysPK in the prediction of these exposition parameters. Physiological and acausal object oriented version systematically under-estimated AUC(0-)(48) and C(max)( )of the parent drug, whereas metabolites were over-estimated when taking the semi-mechanistic and extraction-based metabolism version as the reference. Conclusions: PhysPK has been properly validated, where differences are related to numerical precision of integrators and solvers. A systematic bias for the parent drug and active metabolites was predicted when a semi-mechanistic approach including extraction-based metabolism was compared to the physiologic and acausal approach, showing that interchangeability might be possible when intrinsic-clearance metabolism is implemented in the semi-mechanistic approach. The acausal and object-oriented methodology allows for defining the semi-mechanistic model through its local mechanisms and relationships among entities, without the need to build the final set of Ordinary Differential Equations. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Physiologically-based pharmacokinetic modelling for radiopharmaceuticals using a multilevel object-oriented modelling methodology
    Bouwman, R.
    Herrero, S.
    de With, G.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S44 - S45
  • [2] Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions
    Greupink, Rick
    Schreurs, Marieke
    Benne, Marina S.
    Huisman, Maarten T.
    Russel, Frans G. M.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 49 (05) : 819 - 828
  • [3] A physiologically-based pharmacokinetic (PBPK) model of hydroxychloroquine
    Collins, Keagan P.
    Jackson, Kristen M.
    Gustafson, Daniel L.
    [J]. CANCER RESEARCH, 2017, 77
  • [4] A MECHANISTIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL TO PREDICT THE PHARMACOKINETICS OF R/S-OXAZEPAM AFTER ORAL DOSING
    Turner, David B.
    Pade, Devendra
    Jamei, Masoud
    Neuhoff, Sibylle
    [J]. DRUG METABOLISM REVIEWS, 2015, 47 : 221 - 222
  • [5] Physiologically-based pharmacokinetic (PBPK) model to describe the disposition of pyronaridine
    Diep, John K.
    Lingerfelt, Mary A.
    Ekins, Sean
    Rao, Gauri G.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S34 - S34
  • [6] PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR PANTOPRAZOLE IN CHILDREN WITH OBESITY
    Kyler, K.
    Shakhnovich, V.
    Selvarangan, R.
    Sasidharan, A.
    Chan, S.
    Artz, N.
    Williams, V.
    Friesen, C.
    Pearce, R.
    Gaedigk, A.
    Leeder, J.
    Galetin, A.
    Johnson, T.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S106 - S107
  • [7] APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL IN PREDICTING PREGABALIN PHARMACOKINETICS (PK) IN PEDIATRIC POPULATIONS
    Liu, J.
    Alvey, C. W.
    Chew, M. L.
    Mann, D.
    Pitman, V.
    Corrigan, B.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S77 - S78
  • [8] Physiologically-based pharmacokinetic (PBPK) exploration of extrinsic factors influencing vericiguat pharmacokinetics
    Frechen, S.
    Ince, I.
    Dallmann, A.
    Gerisch, M.
    Jungmann, N.
    Becker, C.
    Lobmeyer, M.
    Trujillo, M.
    Xu, S.
    Burghauss, R.
    Meyer, M.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 3329 - 3329
  • [9] Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
    Miroslav Dostalek
    Iain Gardner
    Brian M. Gurbaxani
    Rachel H. Rose
    Manoranjenni Chetty
    [J]. Clinical Pharmacokinetics, 2013, 52 : 83 - 124
  • [10] Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
    Dostalek, Miroslav
    Gardner, Iain
    Gurbaxani, Brian M.
    Rose, Rachel H.
    Chetty, Manoranjenni
    [J]. CLINICAL PHARMACOKINETICS, 2013, 52 (02) : 83 - 124